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Abstract
Melatonin is a hormone identified in plants and pineal glands of mammals and possesses diverse physiological functions.
Fisetin is a bio-flavonoid widely found in plants and exerts antitumor activity in several types of human cancers. However,
the combinational effect of melatonin and fisetin on antitumor activity, especially in melanoma treatment, remains unclear.
Here, we tested the hypothesis that melatonin could enhance the antitumor activity of fisetin in melanoma cells and
identified the underlying molecular mechanisms. The combinational treatment of melanoma cells with fisetin and
melatonin significantly enhanced the inhibitions of cell viability, cell migration and clone formation, and the induction of
apoptosis when compared with the treatment of fisetin alone. Moreover, such enhancement of antitumor effect by
melatonin was found to be mediated through the modulation of the multiply signaling pathways in melanoma cells. The
combinational treatment of fisetin with melatonin increased the cleavage of PARP proteins, triggered more release of
cytochrome-c from the mitochondrial inter-membrane, enhanced the inhibition of COX-2 and iNOS expression, repressed
the nuclear localization of p300 and NF-kB proteins, and abrogated the binding of NF-kB on COX-2 promoter. Thus, these
results demonstrated that melatonin potentiated the anti-tumor effect of fisetin in melanoma cells by activating
cytochrome-c-dependent apoptotic pathway and inhibiting COX-2/iNOS and NF-kB/p300 signaling pathways, and our study
suggests the potential of such a combinational treatment of natural products in melanoma therapy.
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Introduction
Melanoma is one of the most aggressive forms of skin cancer,
which has been occurring with an increased incidence faster than
that of any other cancer in the world [1–3]. Although melanoma
in early stage is curable, the prognosis and overall survival for
patients with metastasized melanoma is unfavourable. Patients in
metastasis even have a median survival of only 6–10 months [4].
Melanoma is characterized by the forming of resistance to
cytotoxic agents during the progression, and the effective
treatment options for it are very few. Therefore, discovering and
confirming new cytotoxic agents exerting anti-melanoma activities
becomes very important. More and more natural products
extracted from plants and animals have been shown to contribute
to decrease cancer risks, and some of them even have been applied
in cancer chemoprevention and malignancy suppression due to
their high efficiency, low toxicity and wide variety of sources [5–7].
Flavonoids has been suggested to be effective against cancer
[8,9]. Fistin is a major flavonoid extracted from many fruits and
herbal sources, and found to exert anti-aging [10], anti-inflam-
matory [11,12], and anti-viral [13–15] effects. Fisetin displays
antitumor effects in many cancers, including inhibiting tumor cell
growth, inducing tumor cell apoptosis, reducing tumor cell
migration and invasiveness, inducing cell-cycle arrest in cancer
cells, and so on [16–18]. However, its anti-cancer effectiveness is
not powerful enough, and the use of high doses of fisetin is limited
by the emergence of side effects. Therefore, the combinational
treatments with other chemotherapeutic agents, especially natural
antitumor compound, should be improved for fisetin, and the
underlying mechanisms of such combination should also be
identified to achieve higher potency.
Melatonin is a hormone widely found in animals, plants and
microbes. It functions as a powerful antioxidant to protect nuclear
and mitochondrial DNA from damage [19,20]. In addition, as the
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main product of the pineal gland, melatonin has been attracting
more and more attention by exerting anti-proliferative, pro-
apoptotic, and anti-angiogenic properties in multiple types of
cancer cells [21]. Although the underlying molecular mechanism
of antitumor activity for melanoma has not been fully elucidated,
various studies in vivo and in vitro demonstrated that it might be
partially realized through inhibitions of MMP-9 and NF-kB [22],
blocking HIF-1a, STAT3 signaling and VEGF expression [23],
regulating the transcription of cell proliferation-related genes, such
as Nestin, Bmi-1 and Sox2 [24], suppressing the expression of 45S
pre-ribosomal RNA and upstream binding factor [25]. Based on
its ability to affect multiple signaling pathways, its contribution to
diverse physiological functions and its very few side-effects, it
might potentially be a suitable candidate to serve as a partner of
other chemopreventive or chemotherapeutic agents to form a
better and novel treatment strategy for cancer. The underlying
molecular mechanisms of such combination also deserve better
investigation to achieve additional benefits in cancer therapy.
The aberrant or increased activity of COX-2 and the high levels
of its product PGE2 are observed in a variety of cancer types,
especially in colon cancer [26,27]. Many reports have demon-
strated the wide range of effects for COX-2 product PGE2 in
carcinogenesis and tumor development, including inducing
angiogenesis, promoting cellular proliferation, inhibiting cell
apoptosis, stimulating tumor invasion, and so on [28]. In
melanoma, COX-2 is associated with tumor progression [29–
31].Similarly, inducible NO synthases (iNOS) and its product NO
have also shown overexpression in different types of cancer,
including melanoma. iNOS is overexpressed in most cultured
melanoma cells and in human melanoma samples [32,33].
Moreover, its expression has been found to be a strong predictor
of disease-specific and overall survival (OS) for stage III melanoma
patients [34]. Although numerous reports suggested the cytotoxity
of overexpressed NO to cancer cells, the continuous low
expression of intracellular NO like PGE2 has been shown to
promote tumor progression and induce anti-apoptotic effects in
many tumor types. Thus, COX-2 and iNOS represent prime
targets for potential treatment of cancer. Some natural products
extracted from plants have been studied to be able to selectively
inhibit COX-2 and iNOS expression, and have potential to act as
anti-cancer molecules [35–38]. Both COX-2 and iNOS expression
are strictly controlled transcriptionally by the recruitment of
transactivators and coactivators, such as NF-kB and p300, to their
key promoter regions [39–41]. However, whether fisetin could
regulate COX-2 and iNOS expression and whether melatonin
could sensitize or enhance such regulation to further inhibit
melanoma cell growth remains unclear.
In this study, we determined whether melatonin could
potentiate or enhance fisetin’s antitumor effect in human
melanoma cells. We also obtained mechanistic insight into the
action mode of such combination. The combinational effects of
fisetin and melatonin on tumor cell proliferation, migration, and
apoptosis in melanoma cells were analyzed. The expression
changes of some key proteins involved in cell proliferation and
apoptosis signaling pathways and the changes of their upstream
regulatory factors were further analyzed to uncover the underlying
molecular mechanisms of this combinational mode. The findings
from this study showed the potential of such a combinational
treatment in melanoma therapy.
Materials and Methods
Reagents
Fisetin, 1400W, celecoxib (CB) were purchased from Sigma-
Aldrich (St. Louis, USA). Melatonin was purchased from J&K
Chemical Ltd. All reagents were dissolved in DMSO as the initial
concentrate and diluted with medium before adding to the cell.
Cell lines and cell culture
The human melanoma cell lines MeWo and Sk-mel-28 were
cultured as monolayer in RPMI 1640 media supplemented with
10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml
streptomycin and grown under 5% CO2 at 37uC.
MTT assay
Cell viability was measured by a MTT assay. Five replicated
wells were used for each concentration.
Cell migration assay
Cell migration was detected by a scratch assay. Briefly,
melatoma cells were grown to full confluence and treated with
different does of fisetin or melatonin. The confluent cell monolayer
was scraped in a straight line to create ‘scratches’. The images of
the wound gaps were photographed using a phase-contrast
microscope.
Clone formation assay
Melanoma cells were plated in 6-well plates overnight and then
treated with fisetin or melatonin for 24 hrs. The cells were
trypsinized into single cells and were seeded into a 6-well plate at
1000 cells/well. After being incubated at 37uC with 5% CO2 for
14 days, the cells were washed with PBS and fixed with the
mixture (methanol:glacial:acetic 1:1:8) for 10 mins, and stained
with 0.1% crystal violet for 30 mins. The clones with more than 50
cells were counted under an optical microscope.
Apoptosis assay
Apoptosis was measured by Annexin V staining–based FACS
analysis.
Western blot analysis
Total cell lysates were separated in a 10% SDS-PAGE and
electrophoretically transferred to a PVDF membrane. The
proteins were blotted using antibodies and visualized by enhanced
chemiluminescence. The antibodies against b-actin, GAPDH,
PARP, iNOS and COX-2 were obtained from Cell Signaling
Technology and the antibodies against p300, NF-kB p50 and p65
and cytochrome-c were purchased from Santa Cruz Biotechnol-
ogy.
Confocal immunofluorescence
The cells grown on chamber slides and fixed with 4%
paraformaldehyde for 30 mins, permeabilized with 0.2% Tri-
tonX-100 for 5 mins, and blocked with 10% bovine serum
albumin (BSA) in PBS for 30 mins. The antibodies against p300,
p50 or p65 (Santa Cruz) were added to the cells and incubated
overnight at 4uC. Non-immune IgG was included as controls. The
fluorescein isothiocyanate- and rhodamine-conjugated secondary
antibodies diluted in blocking solutions were added and incubated
for 1 hr. The cells were detected with a Leica confocal microscope
and images were processed with Image-Pro Plus 5.1 software.
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Pulldown assay
The nuclear proteins (400 mg) were mixed with double-strand
biotinylated COX-2 promoter probe (4 mg), streptavidin agarose
beads (50 ml) in 500 ml PBSI buffer containing 0.5 mM PMSF,
10 mM NaF, 25 mM b-glycerophosphate and rotated for
overnight at RT. The beads were centrifuged, washed with PBSI
buffer, resuspended with SDS-PAGE loading buffer and boiled at
95uC. The supernatant was analyzed by Western blot.
Immunoprecipitation assay
The nuclear proteins were incubated with the antibodies for
3.5 h at 4uC. The protein-A/G agarose beads were added and the
mixture was incubated at 4uC overnight. After washing with ice-
cold PBSI buffer, the beads were mixed with loading buffer and
boiled. The precipitated proteins were separated by SDS-PAGE
and detected by Western blot analysis using the acetylated-
antibodies.
Statistics analysis
Every experiment was done three times, and the mean values
and standard deviations were calculated using origin 8.0 software.
P,0.05 was considered to be statistical significance.
Results
Melatonin enhanced fisetin-medited cell proliferation
inhibition
MTT assay was used to test the combined effects of fisetin and
melatonin on cell viability in MeWo and Sk-mel-28 cells.
Melatonin alone at the dose from 20 mM to 1000 mM suppressed
melanoma cell viability in a dose-dependent manner (Fig. 1A, 1B).
However, the combinational treatment of the cells with melatonin
(1.0 mM) with fisetin (0 mM–250 mM) significantly enhanced the
inhibition of cell viability as compared with the cells treated with
fisetin alone (Fig. 1C, 1D). The IC50 values of fisetin for cell
proliferation inhibition in MeWo and Sk-mel-28 cells were next
calculated. The combined treatment of fisetin with melatonin
(1.0 mM) resulted in a marked reduction of the IC50 values of
fisetin when compared to the cells treated with fisetin alone
(Fig. 1E).
Melatonin enhanced fisetin-mediated cell morphology
change and clone formation inhibition
We next detected whether melatonin could sensitize fisetin-
mediated changes in cell morphology and inhibition of clone
formation in melanoma cells. The combined treatment led to a
reduced cell-to-cell contact and more shrinkage and even broken
cell morphology compared with the cells treated with melatonin or
fisetin alone (Fig. 2A, 2B). Treated with melatonin or fisetin alone
formed nearly 1000 clones after 7 days’ growth, whereas
combinational treatment of melatonin and fisetin considerably
reduced clone formation, only 600 clones in MeWo cells (Fig. 2C)
and 60 colones in Sk-mel-28 cells (Fig. 2D).
Melatonin enhanced fisetin-mediated cell migration
inhibition
We employed a scratch assay to determine the combined effect
of fisetin with melatonin on cell migration in melanoma cells.
Treatment with melatonin or fisetin (20 mM) alone inhibited cell
migration, but the combined treatment with melatonin markedly
enhanced the fisetin-mediated inhibition of cell migration in
MeWo cells (Fig. 3A). The wounding space between cell layers was
occupied mostly by the migrating cells at 56 h, but the gap of the
cells was not occupied by the migrating cells but a little enlarged in
the MeWo cells cotreated with fisetin and melatonin (Fig. 3A).
Similar enhancement of cell migration inhibition of fisetin by
melatonin was also observed in melanoma Sk-mel-28 cells with
combinational treatment of fisetin and melatonin (Fig. 3B).
Melatonin increased fisetin-induced apoptosis
We analyzed the apoptosis in melanoma cells by FACS
analysis. MeWo cells treated with fisetin alone at the concen-
trations of 20 mM and 50 mM respectively showed 16.5% and
29.6% apoptotic percentage at 48 hours after treatment (Fig. 4A,
4B). By contrast, the combination of fisetin with melatonin
(1 mM) induced nearly 50% apoptotic cells in MeWo cells,
resulting in an obviously increased pro-apoptotic effect (Fig. 4A,
4B). We then analyzed the expression changes of the cleaved
PARP, one of the key proteins associated with apoptosis, in
melanoma cells by Western blot. A marked induction of the
cleaved PARP was deteced in MeWo cells cotreated with fisetin
and melatonin compared with the cells treated with single agent
(Fig. 4C). We also performed immunofluorescence (IF) analysis
to monitor the subcellular localization of cytochrome-c (cyt-c),
an upstream molecule of the caspase cascade-dependent
apoptotic signaling pathway, in melanoma cells. Treatment
with fisetin (20 mM) and melatonin (1 mM) alone for 48 h
triggered the release of cyt-c from the inter-mitochondrial space
into the cytosol in melanoma cells, but the combined treatment
with two agents greatly improved the release of cyt-c
(Fig. 4D,4E).
Melatonin enhanced fisetin-mediated suppression of
COX-2/iNOS signaling
COX-2 and iNOS have been found to be involved in cell
proliferation, migration and invasion in cancer cells. We detected
the expression of COX-2 and iNOS at protein levels by Western
blot. Treatment with fisetin alone at the dose of 20 mM or 50 mM
slightly inhibited COX-2 or iNOS protein expression (Fig. 5A,
5B), while the combinational treatment with melatonin at the dose
of 1.0 mM markedly reduced the expression of COX-2 or iNOS
at protein level in melanoma cells (Fig. 5A, 5B). The MeWo and
Sk-mel-28 cells were pretreated with COX-2-selective inhibitor
celecoxib (CB) at a concentration of 20 mM for 8 h, and followed
by the combined treatment with fisetin (20 mM) and melatonin
(1 mM) for another 48 h. Treatment with CB alone inhibited cell
proliferation, whereas CB pretreatment followed by a combina-
tional treatment with fisetin and melatonin did not significantly
alter cell viability inhibition mediated by the COX-2-selective
inhibitor (Fig. 5C, 5D). Similarly, the co-treatment with fisetin and
melatonin following pretreatment of iNOS-selective inhibitor
1400w in MeWo and Sk-mel-28 cells did not obviously elevate
cell viability inhibition compared with fisetin and melatonin-
induced anti-proliferation ability (Fig. 5E, 5F). These results
indicate that the enhanced antitumor effect of the combinational
treatment might partially be mediated through inactivating COX-
2 and iNOS signalings.
Melatonin enhanced fisetin-mediated inhibition of NF-
kB/p300 signaling
COX-2 and iNOS expression are transcriptionally regulated by
the binding of transactivator NF-kB to their promoter regions and
the further recruitment of co-activator p300 interacting with NF-
kB. We performed immunofluorescence assay to observe the
localization and interaction of p300 and NF-kB in melanoma cells.
The co-localization of p65 with p50 (Fig. 6A) or p300 (Fig. 6B)
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PLOS ONE | www.plosone.org 3 July 2014 | Volume 9 | Issue 7 | e99943
were detected in Sk-mel-28 cells. Treatment with fisetin alone
induced the translocation of NF-kB p50/p65 (Fig.6A) and p300
(Fig. 6B) from the nuclei to cytoplasm, while the combined
treatment with fisetin and melatonin enhanced the translocation of
NF-kB p50/p65 (Fig. 6A) and p300 (Fig. 6B) from nuclei to
cytoplasma. We next determined the binding activity of NF-kB on
COX-2 promoter by a pulldown assay. As shown in Fig. 7A and
7B, the combined treatment with fisetin and melatonin markedly
enhanced the inhibition of NF-kB p50 and p65 binding to COX-2
promoter compared to the treatment with fisetin or melatonin
alone. As p300 has histone acetyltransferase (HAT) activity, we
also determined the effect of the combinational treatment on
p300-mediated acetylation of NF-kB p50/p65. We immunopre-
cipitated the nuclear extracted proteins from melanoma cell lines
MeWo using anti-p50 or anti-p65 antibodies. The acetylated levels
of these transactivators were tested using anti-acetyl-lysine
Figure 1. Melatonin enhanced fisetin-mediated inhibition of cell proliferation. (A–B), Human MeWo (A) and Sk-mel-28 (B) cells were
treated with the indicated doses of melatonin (MT) for 48 hours, and the cell viability was examined by MTT assay. (C–D), MeWo (C) and Sk-mel-28
(D) cells were treated with the indicated doses of fisetin (F) alone or combined with MT (1 mM) for 48 hours, and the cell viability was examined by
MTT assay. (E), The IC50 values of fisetin (F) for cell viability inhibition in cells treated with or without melatonin (MT) were determined. The data is
presented as mean 6 SD of three separate experiments. *, P,0.05, a significant difference compared to the control group.
doi:10.1371/journal.pone.0099943.g001
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Figure 2. Melatonin enhanced fisetin-mediated cell morphology changes and clonal formation inhibitions. (A–B), The cell morphology
changes of MeWo (A) and Sk-mel-28 (B) cells treated with fisetin (F) (20 mM) and melatonin (MT) (1.0 mM) for 48 h were observed. The cells were
photographed using a microscope with a magnification of 40610 fold. (C–D), Clone formation in MeWo (C) and Sk-mel-28 cells(D) treated with fisetin
(F) (20 mM) and melatonin (MT) (1.0 mM) for 48 h were observed.
doi:10.1371/journal.pone.0099943.g002
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antibody. The lower levels of the acetylated p50/p65 proteins
were detected in MeWo cells co-treated with fisetin and melatonin
than that in cell lines treated with single fisetin or melatonin alone
(Fig. 7C, 7D).
Discussion
The role of fisetin in killing cancer cells has been shown by its
augmentative actions on the inhibition of cell proliferation and
induction of cell apoptosis in different cancer cells. However, the
Figure 3. Melatonin enhanced fisetin-mediated cell migration inhibition. (A–B), MeWo (A) or Sk-mel-28 (B) cell monolayer grown to full
confluence was wounded in a line and were left either untreated or treated with indicated doses of fisetin (F) or melatonin (MT) for 56 h. The images
of the wound gap was observed with a magnification of 20610 fold. (C–D), The quantitative analysis of the wound gap in MeWo (C) or Sk-mel-28 (D)
cells treated with fisetin (F) or melatonin (MT) for 56 hours.
doi:10.1371/journal.pone.0099943.g003
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anti-tumor effect of fisetin alone might not be powerful enough
and adjunct therapy might be required to improve its efficacy in
the treatment of cancer. Melatonin is a widely used antioxidant
drug, and its anti-tumor activities have been proved by a number
of studies [42]. Based on its multiple functions and low toxicity in
cancer therapy, melatonin might be used in combination with
Figure 4. Melatonin enhanced fisetin–mediated apoptosis induction. Human MeWo cells were treated with 50 mM fisetin (F) and 1.0 mM
melatonin (MT) for 48 hours. The apoptosis was determined by FACS analysis with annexin-V staining (A, B). The levels of the cleaved PARP protein
(C) was analyzed by Western blot. The immunofluorescence imaging analysis was used to monitor the translocation of cyto-c in MeWo (D) and Sk-
mel-28 (E). The data in (B) is present as the mean 6 SD of three separate experiments. *, P,0.05, significant differences between treatment groups
and DMSO control groups.
doi:10.1371/journal.pone.0099943.g004
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other chemotherapeutic agents to improve therapeutic efficiency.
In the present study, we have demonstrated that melatonin could
potentiate fisetin-mediated antitumor effect in melanoma cells
through activating cytochrome-c/caspase-dependent-apoptotic
pathway, downregulating expression of COX-2 and iNOS
through regulating the nuclear translocation of NF-kB and p300
and abrogating their binding on COX-2 promoter. To our
knowledge, it might be the first time to report the effect of the
combinational treatment of fisetin and melatonin on melanoma
cells and to demonstrate the underlying mechanisms under such a
combinational treatment.
Figure 5. Melatonin enhanced fisetin-mediated suppression of COX-2/iNOS signaling. (A–B), The expression level of COX-2 protein (A)
and iNOS protein (B) were analyzed by Western blot in human MeWo (A) or Sk-mel-28 (B) cells treated with the indicated doses of fisetin (F) (20 mM)
and melatonin (MT) (1 mM or 1 mM) for 48 hours. ‘‘+’’ represents 1 mM MT, and ‘‘++’’ represents 1 mM MT. (C–D), MeWo (C) and Sk-mel-28 (D) cells
were treated with F (20 mM) in combination with MT (1.0 mM) for 48 hours after pretreatment with the COX-2 selective inhibitor celecoxib (CB) (20 or
40 mM) for 24 hours, and the cell viability was determined by MTT analysis. For CB, ‘‘+’’ represents 20 mM, and ‘‘++’’ represents 40 mM. (E–F), MeWo (E)
and Sk-mel-28 cells (F) were treated with the iNOS selective inhibitor 1400w (5 mM) for 24 hours, and then treated with F (20 mM) in combination with
MT (1.0 mM) for 48 hours, and cell viability was determined by MTT analysis. Each data point was calculated from three triplicate groups and the data
is presented as the mean 6 SD. *, P,0.05, significant difference between treatment group and control group.
doi:10.1371/journal.pone.0099943.g005
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The caspase-dependent apoptotic signaling is activated by the
release of cytochrome-c from mitochondria and in turn activates
the downstream execution starting with caspase-3 and the
degradation of several essential cellular proteins such as PARP.
The induction of apoptosis through activation of caspase cascade
by fisetin in cancer cells, including colorectal carcinoma cells,
HeLa cervical cancer cells, and prostate cancer cells, was reported
in several previous studies [43–45]. Our present study also showed
that the activation of caspase signaling cascade contributes to the
enhancement of fisetin-mediated apoptosis by melatonin.
The COX-2 and iNOS signalings are implicated in the
regulation of proliferation, apoptosis, migration and invasion
Figure 6. Melatonin enhanced fisetin-mediated nuclear translocation of p300 and NF-kB. The subcellular localization of p50, p65 and
p300 and the co-localization of p65 with p50 (A) or p65 with p300 (B) in human MeWo cells treated with 20 mM fisetin (F) and 1.0 mM melatonin (MT)
for 48 hours were examined by confocal microscopy. Cells with typical morphology were presented from more than 100 cells at each experiment.
doi:10.1371/journal.pone.0099943.g006
Melatonin Enhances the Anti-Tumor Effect of Fisetin
PLOS ONE | www.plosone.org 9 July 2014 | Volume 9 | Issue 7 | e99943
responses in many kinds of cancer cells, and their inhibitors have
been improved to be able to block survival signaling to accelerate
killing tumor cells. The effective therapeutic strategy targeting
COX-2/iNOS and their related key signaling molecules has been
developed and is expected to provide important therapeutic
implications in cancer treatment. Our present study detected the
enhanced inhibition of COX-2 and iNOS expression in melanoma
cells after co-treatment with fisetin and melatonin in comparison
with single agent treatment, suggesting that inhibition of COX-2
and iNOS signaling at least partially contributed to melatonin
potentiated fisetin-mediated cell proliferation inhibition in mela-
noma cells. Furthermore, we evaluated the possible molecular
mechanisms of such suppression. Although the mechanism by
which COX-2 and iNOS are up-regulated and over-activated in
most cancer cells remains not clear enough, it was reported that
their expressions were transcriptionally controlled by the binding
of multiple transactivators such as c-Jun, C/EBPb and NF-kB and
coactivators such as p300 to the core promoter regions [46]. NF-
kB shows a more extensive role and seems more essential for
COX-2 and iNOS transcriptional activation. Similarly, p300 also
plays a necessary role by exerting a global effect in maintaining
COX-2 and iNOS promoter chromatin structure to increase
recruitment of transactivators, such as NF-kB, and initiate COX-2
and iNOS transcription [47–48]. Our study confirmed the
colocalization of NF-kB and p300 and the enhanced translocation
of these two regulatory elements from nuclei to cytoplasm in
melanoma cells after co-treatment with fisetin and melatonin
through IF analysis. Moreover, we demonstrated that the
increased inhibitory effects on COX-2 expression by the combined
treatment with fisetin and melatonin was very possibly mediated
by promoting p300 and NF-kB translocation from nuclear to
cytosol and further inhibiting their binding to COX-2 promoter,
thereby abrogating COX-2 transcriptional activation in melano-
ma cells. The same mechanism might apply to the elevated
expression inhibition of iNOS signaling in melanoma cells treated
by the combined fisetin and melatonin.
In conclusion, we found that melatonin enhanced the antitumor
activity mediated by fisetin in melanoma cells. Furthermore, we
elucidated the underlying molecular mechanisms of such en-
hanced action. The combined effects of fisetin and melatonin on
melanoma cells might be achieved through activating cytochrome-
c/caspase-dependent apoptotic signaling and inhibiting p300/NF-
kB-mediated COX-2 and iNOS expression. These results not only
indicate the great potential of natural products, such as fisetin and
melatonin, in cancer chemoprevention and therapy, but also
might serve as a basis and direction for the application of the
combinational treatment of natural compounds in improving
therapeutic efficiency for cancers.
Figure 7. Melatonin enhanced fisetin-mediated inhibition of NF-kB binding and acetylation. (A, B), Human MeWo cells were treated with
20 mM fisetin (F) and 1.0 mM melatonin (MT). The binding of p50 and p65 to th biotinylated COX-2 promoter probe (A) was ananlyzed by pulldown
and Western blot, the relative binding activities of p50 and p65 to COX-2 promoter (B) was analyzed by densitometric analysis. (C, D), MeWo cells
were treated with F (20 mM) and MT (1.0 mM). Nuclear lysate from the treated cells was immunoprecipitated with antibodies against p50 and p65.
The acetylated levels of p50 and p65 (C) was analyzed by Western blot, and the acetylated levels of p50 and p65 were quantitatively calculated by
densitometric analysis (D).
doi:10.1371/journal.pone.0099943.g007
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